Gene editing loses its sizzle. CRISPR Therapeutics IPO debuts beneath the range
Some of the bloom has come off the rose of gene editing. CRISPR Therapeutics had to accept $14 a share to launch its IPO …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
